Tokyo – The rollout of recently approved breast cancer and diabetes treatments from international pharmaceutical companies has faced significant delays in Japan, as ongoing negotiations over pricing persist, underscoring concerns among foreign drugmakers about the country’s stringent state-regulated pricing framework.
Also Read
- PSX Weekly Wrap: KSE-100 Sheds 1.6% Amid Hormuz Tensions, Political Noise
- Surge in Institutional Buying of Hyperliquid Strategies: A Genuine Bullish Signal or Just Index Tracking?
- Mourinho’s Real Madrid Secures Late 2-1 Victory Over Espanyol in La Liga Opener
- Tropical Storm Moke Set to Impact Hawaii Amid Ongoing Recovery from Hurricane Lala


